Oncology Drug Snapshot: Axitinib (Inlyta)

Article

This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Related Videos
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Paul Harmatz, MD
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
Related Content
© 2024 MJH Life Sciences

All rights reserved.